COOLER, WHERE TEMPERATURES END UP AND HOW LONG IT TAKES FOR US
TO REBOUND THAT'S COMING UP IN
THE EARLY MORNING. SEVEN DAY,
MIKE, WE'LL SEE IN A FEW
MINUTES. THANK YOU RIGHT NOW. IN
NEW AT 4 30 SOME NEW HOPE IN THE
BATTLE AGAINST CANCER.
PANCREATIC CANCER IS ONE OF THE
MOST DEADLY KILLING 88% OF THOSE
WHO WERE DIAGNOSED. IT'S ALSO
ONE OF THE HARDEST TO TREAT BUT
A NEW EXPERIMENTAL THERAPY. A
PERSONALIZED CANCER VACCINE IS
SHOWING SOME PROMISING RESULTS.
CERTAINLY SOME GOOD NEWS JOINING
US THIS AFTERNOON TO TALK MORE
ABOUT WHAT WE'RE SEEING IN THIS
NEW RESEARCH IS DOCTOR PREGNANT
CARPATHIA, THE ASSISTANT
PROFESSOR OF HEMATOLOGY AND
MEDICAL ONCOLOGY AT UCONN HEALTH
DOCTOR. THANK YOU VERY MUCH FOR
BEING WITH US THIS AFTERNOON.
THANKS FOR HAVING ME. WHAT ARE
WE LEARNING? YOU KNOW WE WERE
TALKING ABOUT THIS VACCINE
EARLIER IN THE WEEK. YOU KNOW ON
THE NEWS. IT'S KIND OF BEEN ALL
OVER THE PLACE. THIS IS
CERTAINLY GOOD NEWS, RIGHT? 100%
I MEAN PANCREATIC CANCER. AS YOU
SAID, IT'S A TOUGH CANCER TO
TREAT OR TREATMENTS RIGHT NOW
ARE LIMITED ESSENTIALLY TO
CHEMOTHERAPY, AND OUR CURE RATES
ARE NOT GREAT. SO ANY NEW
TREATMENTS THAT YOU KNOW, CAN BE
DEVELOPED TO HELP. PEOPLE
SURVIVE ARE. WELCOMED UM AND
THIS IS YOU KNOW SOMETHING VERY
NOVEL, AND THIS IS SOMETHING
THAT ALBEIT IN A SMALL
POPULATION OF PEOPLE, UM, WITH
SHORT TERM FOLLOW UP SHOWS A LOT
OF PROMISE. HOW DOES IT WORK IT
TAILORS TO THE TUMOR OF
INDIVIDUAL PATIENTS, RIGHT. IT'S
KIND OF SPECIALIZED PER PERSON.
EXACTLY SO. THE TREATMENT IS
GIVEN AFTER SOMEBODY HAS
SURGICAL RESECTION OF THE TUMOR
, AND THEN THE PIECE OF THE
TUMOR IS SEQUENCED. TO
UNDERSTAND WHAT MUTATIONS THAT
TUMOR HARBORS AND THE THEN THE M
RNA VACCINE IS CREATED AND
ADMINISTERED TO THE PATIENT. AND
WHAT HAPPENS IN THE PATIENT'S
BODY IS THE M R N A ALLOWS THE
PATIENT TO THEN CREATE THESE, UM
, PROTEINS THAT ARE SEEN IN THE
TUMOR ITSELF. SO FROM THE. A
MUTATION ALLOW ANALYSIS OF THE
TUMOR. WE CAN USE THAT
INFORMATION TO THEN ALLOW A
PATIENT TO CREATE PROTEINS THAT
ALLOWS ONE'S IMMUNE SYSTEM TO
IDENTIFY THOSE PROTEINS AS
SOMETHING FOREIGN AND ALLOWS THE
IMMUNE SYSTEM TO ATTACK THEM.
YOU KNOW, M RNA IS OBVIOUSLY
SOMETHING WE ALL BECAME VERY
FAMILIAR WITH DURING THE
PANDEMIC, AND I BELIEVE BIONTECH
IS INVOLVED IN THIS. WE SEE. DO
YOU THINK A LARGER SCALE UM
RESEARCHER OR SAMPLING PUT OUT
THERE TO SEE IF MAYBE MORE
PEOPLE CAN BENEFIT FROM THIS?
YES AND I THINK THAT YOU KNOW
THAT IS PLANNED AND I THINK THE
TRIALS ARE GOING TO BE LOOKING
AT THE TRIALS WILL BE OPEN AND
MULTIPLE SITES THAT THESE
PATIENTS ALL CAME FROM MEMORIAL
SLOAN KETTERING IN NEW YORK. BUT
THE FOLLOW UP STUDY WILL INCLUDE
PATIENTS FROM ALL OVER THE
COUNTRY AND LARGER NUMBERS OF
PATIENTS. AND THAT IS REALLY THE
INFORMATION THAT WILL HELP US
UNDERSTAND IS THIS REALLY
RELEVANT TO LARGE POPULATIONS OF
PEOPLE. WHAT ARE THE SORT OF,
YOU KNOW LONG TERM BENEFITS? UM
AND YOU KNOW, HOW CAN THIS BE
INTEGRATED INTO OUR TREATMENT
FOR PATIENTS WITH PANCREATIC
CANCER? WELL, CERTAINLY EVERYONE
IS IMPACTED BY CANCER AND THEIR
FAMILY IN ONE WAY OR ANOTHER. DO
YOU THINK THERE IS HOPE RIGHT
NOW FOR MAYBE SOME OTHER CANCER
CANCER VACCINE TRIALS, MAYBE
SOME OTHER POSITIVE NEWS. SO WE
HAVE HAD SOME POSITIVE NEWS WITH
MELANOMA AND CANCER VACCINE
TRIALS. AND YOU KNOW THE HOPE IS
THAT ONCE THIS IS, UM PROVEN TO
BE BENEFICIAL, AND WE SEE YOU
KNOW IT GOING IN REAL TIME. I DO
THINK THAT THE USE OF IT WILL BE
EXPANDED, YOU KNOW? HOPEFULLY
THE OTHER TUMOR TYPES ANYTHING.
I'M SURE YOU WOULD AGREE. AND
THAT MOVES US IN THE RIGHT
DIRECTION IS CERTAINLY A GOOD
THING. DR KAPADIA. THANK YOU
VERY MUCH FOR JOINING